Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
May 19, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on...
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 16, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter with cash and cash...
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
May 04, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on...
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th
March 22, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
February 24, 2022 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Closing of $10 Million Financing
February 16, 2022 09:26 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct Offering
February 11, 2022 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma
February 09, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced...
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04
January 24, 2022 09:25 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 Conference
January 10, 2022 09:03 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...